27 results on '"Liberatore, Giuseppe"'
Number of results to display per page
Search Results
2. Frequency and clinical correlates of anti-nerve antibodies in a large population of CIDP patients included in the Italian database
- Author
-
Liberatore, Giuseppe, De Lorenzo, Alberto, Giannotta, Claudia, Manganelli, Fiore, Filosto, Massimiliano, Cosentino, Giuseppe, Cocito, Dario, Briani, Chiara, Cortese, Andrea, Fazio, Raffaella, Lauria, Giuseppe, Clerici, Angelo Maurizio, Rosso, Tiziana, Marfia, Girolama Alessandra, Antonini, Giovanni, Cavaletti, Guido, Carpo, Marinella, Doneddu, Pietro Emiliano, Spina, Emanuele, Cotti Piccinelli, Stefano, Peci, Erdita, Querol, Luis, and Nobile-Orazio, Eduardo
- Published
- 2022
- Full Text
- View/download PDF
3. Prolonged distal motor latency of median nerve does not improve diagnostic accuracy for CIDP
- Author
-
Spina, Emanuele, Doneddu, Pietro Emiliano, Liberatore, Giuseppe, Cocito, Dario, Fazio, Raffaella, Briani, Chiara, Filosto, Massimiliano, Benedetti, Luana, Antonini, Giovanni, Cosentino, Giuseppe, Jann, Stefano, Mazzeo, Anna, Cortese, Andrea, Marfia, Girolama Alessandra, Clerici, Angelo Maurizio, Siciliano, Gabriele, Carpo, Marinella, Luigetti, Marco, Lauria, Giuseppe, Rosso, Tiziana, Cavaletti, Guido, Peci, Erdita, Tronci, Stefano, Ruiz, Marta, Piccinelli, Stefano Cotti, Schenone, Angelo, Leonardi, Luca, Gentile, Luca, Piccolo, Laura, Mataluni, Giorgia, Santoro, Lucio, Nobile-Orazio, Eduardo, and Manganelli, Fiore
- Published
- 2022
- Full Text
- View/download PDF
4. Prospective open- label trial with rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy not responding to conventional immune therapies.
- Author
-
Doneddu, Pietro Emiliano, Cocito, Dario, Fazio, Raffaella, Benedetti, Luana, Peci, Erdita, Liberatore, Giuseppe, Falzone, Yuri Matteo, Germano, Francesco, Gallia, Francesca, Giannotta, Claudia, Lleixà, Cinta, Bianchi, Elisa, and Nobile-Orazio, Eduardo
- Subjects
CHRONIC inflammatory demyelinating polyradiculoneuropathy ,HEMATOPOIETIC stem cell transplantation ,B cell differentiation ,NERVE conduction studies ,MEDICAL sciences ,POLYNEUROPATHIES ,HEART failure - Published
- 2024
- Full Text
- View/download PDF
5. The neurophysiological lesson from the Italian CIDP database
- Author
-
Spina, Emanuele, Doneddu, Pietro Emiliano, Liberatore, Giuseppe, Cocito, Dario, Fazio, Raffaella, Briani, Chiara, Filosto, Massimiliano, Benedetti, Luana, Antonini, Giovanni, Cosentino, Giuseppe, Jann, Stefano, Mazzeo, Anna, Cortese, Andrea, Marfia, Girolama Alessandra, Clerici, Angelo Maurizio, Siciliano, Gabriele, Carpo, Marinella, Luigetti, Marco, Lauria, Giuseppe, Rosso, Tiziana, Cavaletti, Guido, Peci, Erdita, Tronci, Stefano, Ruiz, Marta, Piccinelli, Stefano Cotti, Schenone, Angelo, Leonardi, Luca, Gentile, Luca, Piccolo, Laura, Mataluni, Giorgia, Santoro, Lucio, Nobile-Orazio, Eduardo, and Manganelli, Fiore
- Published
- 2022
- Full Text
- View/download PDF
6. Cytokines and chemokines in patients with chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy: A systematic review
- Author
-
Cutellè, Claudia, primary, De Lorenzo, Alberto, additional, Doneddu, Pietro Emiliano, additional, Creta, Maria Francesca, additional, Selmi, Carlo, additional, Liberatore, Giuseppe, additional, Giordano, Andrea, additional, Gentile, Francesco, additional, Erre, Gian Luca, additional, and Nobile‐Orazio, Eduardo, additional
- Published
- 2024
- Full Text
- View/download PDF
7. Correction to: Frequency and clinical correlates of anti-nerve antibodies in a large population of CIDP patients included in the Italian database
- Author
-
Liberatore, Giuseppe, primary, De Lorenzo, Alberto, additional, Giannotta, Claudia, additional, Manganelli, Fiore, additional, Filosto, Massimiliano, additional, Cosentino, Giuseppe, additional, Cocito, Dario, additional, Briani, Chiara, additional, Cortese, Andrea, additional, Fazio, Raffaella, additional, Lauria, Giuseppe, additional, Clerici, Angelo Maurizio, additional, Rosso, Tiziana, additional, Marfia, Girolama Alessandra, additional, Antonini, Giovanni, additional, Cavaletti, Guido, additional, Carpo, Marinella, additional, Doneddu, Pietro Emiliano, additional, Spina, Emanuele, additional, Cotti Piccinelli, Stefano, additional, Peci, Erdita, additional, Querol, Luis, additional, and Nobile‑Orazio, Eduardo, additional
- Published
- 2023
- Full Text
- View/download PDF
8. COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context
- Author
-
Sormani, Maria Pia, Schiavetti, Irene, Carmisciano, Luca, Cordioli, Cinzia, Filippi, Massimo, Radaelli, Marta, Immovilli, Paolo, Capobianco, Marco, De Rossi, Nicola, Brichetto, Giampaolo, Cocco, Eleonora, Scandellari, Cinzia, Cavalla, Paola, Pesci, Ilaria, Zito, Antonio, Confalonieri, Paolo, Marfia, Girolama Alessandra, Perini, Paola, Inglese, Matilde, Trojano, Maria, Brescia Morra, Vincenzo, Tedeschi, Gioacchino, Comi, Giancarlo, Battaglia, Mario Alberto, Patti, Francesco, Salvetti, Marco, Abbadessa, Gianmarco, Aguglia, Umberto, Allegorico, Lia, Allegri Rossi, Beatrice Maria, Amato, Maria Pia, Annovazzi, Pietro, Antozzi, Carlo, Appendino, Lucia, Arena, Sebastiano, Baione, Viola, Balgera, Roberto, Barcella, Valeria, Baroncini, Damiano, Barrilà, Caterina, Bellacosa, Alessandra, Bellucci, Gianmarco, Bergamaschi, Roberto, Bergamaschi, Valeria, Bezzini, Daiana, Biolzi, Beatrice, Bisecco, Alvino, Bonavita, Simona, Borriello, Giovanna, Bosa, Chiara, Bosco, Antonio, Bovis, Francesca, Bozzali, Marco, Brambilla, Laura, Buccafusca, Maria, Bucciantini, Elisabetta, Bucello, Sebastiano, Buscarinu, Maria Chiara, Cabboi, Maria Paola, Calabrese, Massimiliano, Calabria, Francesca, Caleri, Francesca, Camilli, Federico, Caniatti, Luisa Maria, Cantello, Roberto, Capra, Ruggero, Capuano, Rocco, Carta, Patrizia, Celani, Maria Grazia, Cellerino, Maria, Cerqua, Raffaella, Chisari, Clara, Clerici, Raffaella, Clerico, Marinella, Cola, Gaia, Conte, Antonella, Conti, Marta Zaffira, Cordano, Christian, Cordera, Susanna, Corea, Francesco, Correale, Claudio, Cottone, Salvatore, Crescenzo, Francesco, Curti, Erica, dʼAmbrosio, Alessandro, DʼAmico, Emanuele, Danni, Maura Chiara, dʼArma, Alessia, Dattola, Vincenzo, de Biase, Stefano, Luca, Giovanna De, Mercanti, Stefania Federica De, De Mitri, Paolo, De Stefano, Nicola, Cava, Marco Della, Napoli, Mario di, Sapio, Alessia Di, Docimo, Renato, Dutto, Anna, Evangelista, Luana, Fanara, Salvatore, Diana, Ferraro, Ferrò, Maria Teresa, Fioretti, Cristina, Fratta, Mario, Frau, Jessica, Fronza, Marzia, Furlan, Roberto, Gajofatto, Alberto, Gallo, Antonio, Gallo, Paolo, Gasperini, Claudio, Ghazaryan, Anna, Giometto, Bruno, Gobbin, Francesca, Govone, Flora, Granella, Franco, Grange, Erica, Grasso, Maria Grazia, Guareschi, Angelica, Guaschino, Clara, Guerrieri, Simone, Guidetti, Donata, Iaffaldano, Pietro, Ianniello, Antonio, Iasevoli, Luigi, Imperiale, Daniele, Infante, Maria Teresa, Iodice, Rosa, Iovino, Aniello, Konrad, Giovanna, Landi, Doriana, Lanzillo, Roberta, Lapucci, Caterina, Lavorgna, Luigi, LʼEpiscopo, Maria Rita, Leva, Serena, Liberatore, Giuseppe, Lo Re, Marianna, Longoni, Marco, Lopiano, Leonardo, Lorefice, Lorena, Lucchini, Matteo, Lus, Giacomo, Maimone, Davide, Malentacchi, Maria, Mallucci, Giulia, Malucchi, Simona, Mancinelli, Chiara Rosa, Mancinelli, Luca, Manganotti, Paolo, Maniscalco, Giorgia Teresa, Mantero, Vittorio, Marangoni, Sabrina, Marastoni, Damiano, Marinelli, Fabiana, Marti, Alessandro, Boneschi, Filippo Martinelli, Masserano Zoli, Federco, Matta, Francesca, Mendozzi, Laura, Meucci, Giuseppe, Miante, Silvia, Miele, Giuseppina, Milano, Eva, Mirabella, Massimiliano, Missione, Rosanna, Moccia, Marcello, Moiola, Lucia, Montepietra, Sara, MontiBragadin, Margherita, Montini, Federico, Motta, Roberta, Nardone, Raffaele, Nicoletti, Carolina Gabri, Nobile-Orazio, Eduardo, Nozzolillo, Agostino, Onofrj, Marco, Orlandi, Riccardo, Palmieri, Anna, Paolicelli, Damiano, Pasquali, Livia, Pastò, Luisa, Pedrazzoli, Elisabetta, Petracca, Maria, Petrone, Alfredo, Piantadosi, Carlo, Pietroboni, Anna M, Pinardi, Federica, Ponzano, Marta, Portaccio, Emilio, Pozzato, Mattia, Pozzilli, Carlo, Prosperini, Luca, Protti, Alessandra, Ragonese, Paolo, Rasia, Sarah, Realmuto, Sabrina, Repice, Anna, Rigoni, Eleonora, Rilla, Maria Teresa, Rinaldi, Francesca, Romano, Calogero Marcello, Ronzoni, Marco, Rovaris, Marco, Ruscica, Francesca, Sabattini, Loredana, Salemi, Giuseppe, Saraceno, Lorenzo, Sartori, Alessia, Sartori, Arianna, Sbragia, Elvira, Scarano, Giuditta Ilaria, Scarano, Valentina, Schillaci, Valentina, Sessa, Maria, Sgarito, Caterina, Sibilia, Grazia, Siciliano, Gabriele, Signori, Alessio, Signoriello, Elisabetta, Sinisi, Leonardo, Sireci, Francesca, Sola, Patrizia, Solaro, Claudio, Sotgiu, Stefano, Sparaco, Maddalena, Stromillo, Maria Laura, Strumia, Silvia, Susani, Emanuela Laura, Tabiadon, Giulietta, Teatini, Francesco, Tomassini, Valentina, Tonietti, Simone, Torri, Clerici Valentina, Tortorella, Carla, Toscano, Simona, Totaro, Rocco, Trotta, Maria, Turano, Gabriella, Ulivelli, Monica, Valentino, Manzo, Vaula, Giovanna, Vecchio, Domizia, Vercellino, Marco, Verrengia, Elena Pinuccia, Vianello, Marika, Virgilio, Eleonora, Vitetta, Francesca, Vollaro, Stefano, Zaffaroni, Mauro, Zampolini, Mauro, Zarbo, Ignazio Roberto, and Zuliani, Luigi
- Published
- 2022
- Full Text
- View/download PDF
9. Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy
- Author
-
Martín-Aguilar, Lorena, Lleixà, Cinta, Pascual-Goñi, Elba, Caballero-Ávila, Marta, Martínez-Martínez, Laura, Díaz-Manera, Jordi, Rojas-García, Ricard, Cortés-Vicente, Elena, Turon-Sans, Janina, de Luna, Noemi, Suárez-Calvet, Xavier, Gallardo, Eduard, Rajabally, Yusuf, Scotton, Sangeeta, Jacobs, Bart C., Baars, Adája, Cortese, Andrea, Vegezzi, Elisa, Höftberger, Romana, Zimprich, Fritz, Roesler, Cornelia, Nobile-Orazio, Eduardo, Liberatore, Giuseppe, Hiew, Fu Liong, Martínez-Piñeiro, Alicia, Carvajal, Alejandra, Piñar-Morales, Raquel, Usón-Martín, Mercedes, Albertí, Olalla, López-Pérez, Maria Ángeles, Márquez, Fabian, Pardo-Fernández, Julio, Muñoz-Delgado, Laura, Cabrera-Serrano, Macarena, Ortiz, Nicolau, Bartolomé, Manuel, Duman, Özgür, Bril, Vera, Segura-Chávez, Darwin, Pitarokoili, Kalliopi, Steen, Claudia, Illa, Isabel, and Querol, Luis
- Published
- 2022
- Full Text
- View/download PDF
10. Impact of 2021 European Academy of Neurology/Peripheral Nerve Society diagnostic criteria on diagnosis and therapy of chronic inflammatory demyelinating polyradiculoneuropathy variants.
- Author
-
De Lorenzo, Alberto, Liberatore, Giuseppe, Doneddu, Pietro Emiliano, Manganelli, Fiore, Cocito, Dario, Briani, Chiara, Fazio, Raffaella, Mazzeo, Anna, Schenone, Angelo, Di Stefano, Vincenzo, Cosentino, Giuseppe, Marfia, Girolama Alessandra, Benedetti, Luana, Carpo, Marinella, Filosto, Massimiliano, Antonini, Giovanni, Clerici, Angelo Maurizio, Luigetti, Marco, Matà, Sabrina, and Rosso, Tiziana
- Subjects
- *
CHRONIC inflammatory demyelinating polyradiculoneuropathy , *PERIPHERAL nervous system , *POLYNEUROPATHIES , *ACTION potentials - Abstract
Background and purpose: There are different criteria for the diagnosis of different variants of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The 2021 European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) guidelines provide specific clinical criteria for each CIDP variant even if their therapeutical impact has not been investigated. Methods: We applied the clinical criteria for CIDP variants of the 2021 EAN/PNS guidelines to 369 patients included in the Italian CIDP database who fulfilled the 2021 EAN/PNS electrodiagnostic criteria for CIDP. Results: According to the 2021 EAN/PNS clinical criteria, 245 patients achieved a clinical diagnosis of typical CIDP or CIDP variant (66%). We identified 106 patients with typical CIDP (29%), 62 distal CIDP (17%), 28 multifocal or focal CIDP (7%), four sensory CIDP (1%), 27 sensory‐predominant CIDP (7%), 10 motor CIDP (3%), and eight motor‐predominant CIDP (2%). Patients with multifocal, distal, and sensory CIDP had milder impairment and symptoms. Patients with multifocal CIDP had less frequently reduced conduction velocity and prolonged F‐wave latency and had lower levels of cerebrospinal fluid protein. Patients with distal CIDP more frequently had reduced distal compound muscle action potentials. Patients with motor CIDP did not improve after steroid therapy, whereas those with motor‐predominant CIDP did. None of the patients with sensory CIDP responded to steroids, whereas most of those with sensory‐predominant CIDP did. Conclusions: The 2021 EAN/PNS criteria for CIDP allow a better characterization of CIDP variants, permitting their distinction from typical CIDP and more appropriate treatment for patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Unclassified clinical presentations of chronic inflammatory demyelinating polyradiculoneuropathy
- Author
-
Doneddu, Pietro Emiliano, primary, Akyil, Houseyin, additional, Manganelli, Fiore, additional, Briani, Chiara, additional, Cocito, Dario, additional, Benedetti, Luana, additional, Mazzeo, Anna, additional, Fazio, Raffaella, additional, Filosto, Massimiliano, additional, Cosentino, Giuseppe, additional, Di Stefano, Vincenzo, additional, Antonini, Giovanni, additional, Marfia, Girolama Alessandra, additional, Inghilleri, Maurizio, additional, Siciliano, Gabriele, additional, Clerici, Angelo Maurizio, additional, Carpo, Marinella, additional, Schenone, Angelo, additional, Luigetti, Marco, additional, Lauria, Giuseppe, additional, Matà, Sabrina, additional, Rosso, Tiziana, additional, Minicuci, Giacomo Maria, additional, Lucchetta, Marta, additional, Cavaletti, Guido, additional, Liberatore, Giuseppe, additional, Spina, Emanuele, additional, Campagnolo, Marta, additional, Peci, Erdita, additional, Germano, Francesco, additional, Gentile, Luca, additional, Strano, Camilla, additional, Cotti Piccinelli, Stefano, additional, Vegezzi, Elisa, additional, Leonardi, Luca, additional, Mataluni, Giorgia, additional, Ceccanti, Marco, additional, Schirinzi, Erika, additional, Romozzi, Marina, additional, and Nobile-Orazio, Eduardo, additional
- Published
- 2023
- Full Text
- View/download PDF
12. The circular RNA landscape in multiple sclerosis: Disease-specific associated variants and exon methylation shape circular RNA expression profile
- Author
-
Cardamone, Giulia, primary, Paraboschi, Elvezia Maria, additional, Soldà, Giulia, additional, Liberatore, Giuseppe, additional, Rimoldi, Valeria, additional, Cibella, Javier, additional, Airi, Federica, additional, Tisato, Veronica, additional, Cantoni, Claudia, additional, Gallia, Francesca, additional, Gemmati, Donato, additional, Piccio, Laura, additional, Duga, Stefano, additional, Nobile-Orazio, Eduardo, additional, and Asselta, Rosanna, additional
- Published
- 2023
- Full Text
- View/download PDF
13. Comparison of the diagnostic accuracy of the 2021 EAN/PNS and 2010 EFNS/PNS diagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy
- Author
-
Doneddu, Pietro Emiliano, primary, De Lorenzo, Alberto, additional, Manganelli, Fiore, additional, Cocito, Dario, additional, Fazio, Raffaella, additional, Briani, Chiara, additional, Mazzeo, Anna, additional, Filosto, Massimiliano, additional, Cosentino, Giuseppe, additional, Benedetti, Luana, additional, Schenone, Angelo, additional, Marfia, Girolama Alessandra, additional, Antonini, Giovanni, additional, Matà, Sabrina, additional, Luigetti, Marco, additional, Liberatore, Giuseppe, additional, Spina, Emanuele, additional, Peci, Erdita, additional, Strano, Camilla, additional, Cacciavillani, Mario, additional, Gentile, Luca, additional, Cotti Piccinelli, Stefano, additional, Cortese, Andrea, additional, Bianchi, Elisa, additional, and Nobile-Orazio, Eduardo, additional
- Published
- 2022
- Full Text
- View/download PDF
14. Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies
- Author
-
Schiavetti, Irene, primary, Cordioli, Cinzia, additional, Stromillo, Maria Laura, additional, Teresa Ferrò, Maria, additional, Laroni, Alice, additional, Cocco, Eleonora, additional, Cola, Gaia, additional, Pasquali, Livia, additional, Rilla, Maria Teresa, additional, Signoriello, Elisabetta, additional, Iodice, Rosa, additional, Di Sapio, Alessia, additional, Lanzillo, Roberta, additional, Caleri, Francesca, additional, Annovazzi, Pietro, additional, Conte, Antonella, additional, Liberatore, Giuseppe, additional, Ruscica, Francesca, additional, Docimo, Renato, additional, Bonavita, Simona, additional, Ulivelli, Monica, additional, Cavalla, Paola, additional, Patti, Francesco, additional, Ferraro, Diana, additional, Clerico, Marinella, additional, Immovilli, Paolo, additional, Di Filippo, Massimiliano, additional, Salvetti, Marco, additional, and Sormani, Maria Pia, additional
- Published
- 2022
- Full Text
- View/download PDF
15. Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy
- Author
-
Sormani, Maria Pia, primary, Schiavetti, Irene, additional, Inglese, Matilde, additional, Carmisciano, Luca, additional, Laroni, Alice, additional, Lapucci, Caterina, additional, Visconti, Valeria, additional, Serrati, Carlo, additional, Gandoglia, Ilaria, additional, Tassinari, Tiziana, additional, Perego, Germana, additional, Brichetto, Giampaolo, additional, Gazzola, Paola, additional, Mannironi, Antonio, additional, Stromillo, Maria Laura, additional, Cordioli, Cinzia, additional, Landi, Doriana, additional, Clerico, Marinella, additional, Signoriello, Elisabetta, additional, Cocco, Eleonora, additional, Frau, Jessica, additional, Ferrò, Maria Teresa, additional, Di Sapio, Alessia, additional, Pasquali, Livia, additional, Ulivelli, Monica, additional, Marinelli, Fabiana, additional, Pizzorno, Matteo, additional, Callari, Graziella, additional, Iodice, Rosa, additional, Liberatore, Giuseppe, additional, Caleri, Francesca, additional, Repice, Anna Maria, additional, Cordera, Susanna, additional, Battaglia, Mario Alberto, additional, Salvetti, Marco, additional, Franciotta, Diego, additional, Uccelli, Antonio, additional, Maglione, Alessandro, additional, Sapio, Alessia Di, additional, Signori, Alessio, additional, Iovino, Aniello, additional, Maria Repice, Anna, additional, Gabri Nicoletti, Carolina, additional, Mancinelli, Chiara Rosa, additional, Bezzini, Daiana, additional, Carmagnini, Daniele, additional, Brogi, Davide, additional, Nobile Orazio, Eduardo, additional, Nako, Enri, additional, Assandrir, Ester, additional, Baldi, Federica, additional, Ansaldi, Filippo, additional, Bovis, Francesca, additional, Siciliano, Gabriele, additional, Cola, Gaia, additional, Lus, Giacomo, additional, Icardi, Giancarlo, additional, Bellucci, Gianmarco, additional, Da Rin, Giorgio, additional, Alessandra Marfia, Girolama, additional, Vazzoler, Giulia, additional, Trivelli, Giuseppe, additional, Maietta, Ilaria, additional, Sticchi, Laura, additional, Lorefice, Lorena, additional, Ruggiero, Lucia, additional, Manzino, Marcello, additional, Monti Bragadin, Margherita, additional, Chiara Buscarinu, Maria, additional, Gagliardi, Maria, additional, Laura Stromillo, Maria, additional, Pia Sormani, Maria, additional, Rilla, Maria Teresa, additional, Alberto Battaglia, Mario, additional, Ponzano, Marta, additional, Fronza, Marzia, additional, Del Sette, Massimo, additional, Scialabba, Matteo, additional, Bedognetti, Michele, additional, De Rossi, Nicola, additional, De Stefano, Nicola, additional, Bigi, Rachele, additional, Dubbioso, Raffaele, additional, Reniè, Roberta, additional, Fabbri, Sabrina, additional, Rasia, Sarah, additional, Rolla, Simona, additional, Platzgummer, Stefan, additional, and Carlini, Valentina, additional
- Published
- 2022
- Full Text
- View/download PDF
16. A diagnostic score for anti‐myelin‐associated‐glycoprotein neuropathy or chronic inflammatory demyelinating polyradiculoneuropathy in patients with anti‐myelin‐associated‐glycoprotein antibody.
- Author
-
Doneddu, Pietro E., Ruiz, Marta, Bianchi, Elisa, Liberatore, Giuseppe, Manganelli, Fiore, Cocito, Dario, Cosentino, Giuseppe, Benedetti, Luana, Marfia, Girola A., Filosto, Massimiliano, Briani, Chiara, Giannotta, Claudia, and Nobile‐Orazio, Eduardo
- Subjects
CHRONIC inflammatory demyelinating polyradiculoneuropathy ,POLYNEUROPATHIES ,MYELIN sheath diseases ,NEUROPATHY - Abstract
Background and purpose: A diagnostic score was developed to discriminate anti‐myelin‐associated‐glycoprotein (MAG) neuropathy from chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and applied it to patients with atypical anti‐MAG neuropathy. Methods: The clinical and electrophysiological features of patients with a diagnosis of typical anti‐MAG neuropathy were compared to those of patients with a diagnosis of CIDP. The association of each feature with the diagnosis was assessed in the two groups. Features showing a significant association with the diagnosis were included in a multivariable logistic regression model and adjusted odds ratios were estimated for each feature. A score ranging from 1 to 3 was applied to each feature based on the magnitude of the estimated odds ratios. The score was then applied to patients with a clinical diagnosis of CIDP who also had high anti‐MAG antibody titers (CIDP‐MAG). Results: Thirty‐one anti‐MAG neuropathy patients, 45 typical CIDP patients and 16 CIDP‐MAG patients were included. Scores in anti‐MAG antibody patients ranged from 1 to 5 and in CIDP patients from −7 to −1. Using the score, 4/16 CIDP‐MAG patients were diagnosed to have anti‐MAG neuropathy and 12/16 patients to have CIDP. Response to intravenous immunoglobulin in the CIDP‐MAG patients classified as CIDP was similar to that of definite CIDP patients and higher than that of anti‐MAG neuropathy patients. Conclusions: Our score allowed an accurate discrimination to be made, amongst patients with anti‐MAG antibodies, of those affected by CIDP and the patients with anti‐MAG neuropathy. This score may help proper treatment to be chosen for patients with anti‐MAG antibodies with a CIDP‐like presentation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. A diagnostic score for anti‐myelin‐associated‐glycoprotein neuropathy or chronic inflammatory demyelinating polyradiculoneuropathy in patients with anti‐myelin‐associated‐glycoprotein antibody
- Author
-
Doneddu, Pietro E., primary, Ruiz, Marta, additional, Bianchi, Elisa, additional, Liberatore, Giuseppe, additional, Manganelli, Fiore, additional, Cocito, Dario, additional, Cosentino, Giuseppe, additional, Benedetti, Luana, additional, Marfia, Girola A., additional, Filosto, Massimiliano, additional, Briani, Chiara, additional, Giannotta, Claudia, additional, and Nobile‐Orazio, Eduardo, additional
- Published
- 2022
- Full Text
- View/download PDF
18. A diagnostic score for anti-MAG neuropathy or CIDP in patients with anti-MAG antibody
- Author
-
Doneddu, Pietro E, Ruiz, Marta, Bianchi, Elisa, Liberatore, Giuseppe, Manganelli, Fiore, Cocito, Dario, Cosentino, Giuseppe, Benedetti, Luana, Marfia, Girola A, Filosto, Massimiliano, Briani, Chiara, Giannotta, Claudia, and Nobile-Orazio, Eduardo
- Subjects
chronic inflammatory demyelinating polyradiculoneuropathy ,antibody ,diagnostic criteria ,neuropathy ,CIDP ,MAG - Published
- 2022
19. sj-docx-1-msj-10.1177_13524585221102918 – Supplemental material for Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies
- Author
-
Schiavetti, Irene, Cordioli, Cinzia, Stromillo, Maria Laura, Teresa Ferrò, Maria, Laroni, Alice, Cocco, Eleonora, Cola, Gaia, Pasquali, Livia, Rilla, Maria Teresa, Signoriello, Elisabetta, Iodice, Rosa, Di Sapio, Alessia, Lanzillo, Roberta, Caleri, Francesca, Annovazzi, Pietro, Conte, Antonella, Liberatore, Giuseppe, Ruscica, Francesca, Docimo, Renato, Bonavita, Simona, Ulivelli, Monica, Cavalla, Paola, Patti, Francesco, Ferraro, Diana, Clerico, Marinella, Immovilli, Paolo, Di Filippo, Massimiliano, Salvetti, Marco, and Sormani, Maria Pia
- Subjects
FOS: Clinical medicine ,111702 Aged Health Care ,FOS: Health sciences ,110904 Neurology and Neuromuscular Diseases - Abstract
Supplemental material, sj-docx-1-msj-10.1177_13524585221102918 for Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies by Irene Schiavetti, Cinzia Cordioli, Maria Laura Stromillo, Maria Teresa Ferrò, Alice Laroni, Eleonora Cocco, Gaia Cola, Livia Pasquali, Maria Teresa Rilla, Elisabetta Signoriello, Rosa Iodice, Alessia Di Sapio, Roberta Lanzillo, Francesca Caleri, Pietro Annovazzi, Antonella Conte, Giuseppe Liberatore, Francesca Ruscica, Renato Docimo, Simona Bonavita, Monica Ulivelli, Paola Cavalla, Francesco Patti, Diana Ferraro, Marinella Clerico, Paolo Immovilli, Massimiliano Di Filippo, Marco Salvetti and Maria Pia Sormani in Multiple Sclerosis Journal
- Published
- 2022
- Full Text
- View/download PDF
20. Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy
- Author
-
Martín-Aguilar, Lorena, primary, Lleixà, Cinta, additional, Pascual-Goñi, Elba, additional, Caballero-Ávila, Marta, additional, Martínez-Martínez, Laura, additional, Díaz-Manera, Jordi, additional, Rojas-García, Ricard, additional, Cortés-Vicente, Elena, additional, Turon-Sans, Janina, additional, de Luna, Noemi, additional, Suárez-Calvet, Xavier, additional, Gallardo, Eduard, additional, Rajabally, Yusuf, additional, Scotton, Sangeeta, additional, Jacobs, Bart C., additional, Baars, Adája, additional, Cortese, Andrea, additional, Vegezzi, Elisa, additional, Höftberger, Romana, additional, Zimprich, Fritz, additional, Roesler, Cornelia, additional, Nobile-Orazio, Eduardo, additional, Liberatore, Giuseppe, additional, Hiew, Fu Liong, additional, Martínez-Piñeiro, Alicia, additional, Carvajal, Alejandra, additional, Piñar-Morales, Raquel, additional, Usón-Martín, Mercedes, additional, Albertí, Olalla, additional, López-Pérez, Maria Ángeles, additional, Márquez, Fabian, additional, Pardo-Fernández, Julio, additional, Muñoz-Delgado, Laura, additional, Cabrera-Serrano, Macarena, additional, Ortiz, Nicolau, additional, Bartolomé, Manuel, additional, Duman, Özgür, additional, Bril, Vera, additional, Segura-Chávez, Darwin, additional, Pitarokoili, Kalliopi, additional, Steen, Claudia, additional, Illa, Isabel, additional, and Querol, Luis, additional
- Published
- 2021
- Full Text
- View/download PDF
21. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies
- Author
-
Sormani, Maria Pia, primary, Inglese, Matilde, additional, Schiavetti, Irene, additional, Carmisciano, Luca, additional, Laroni, Alice, additional, Lapucci, Caterina, additional, Da Rin, Giorgio, additional, Serrati, Carlo, additional, Gandoglia, Ilaria, additional, Tassinari, Tiziana, additional, Perego, Germana, additional, Brichetto, Giampaolo, additional, Gazzola, Paola, additional, Mannironi, Antonio, additional, Stromillo, Maria Laura, additional, Cordioli, Cinzia, additional, Landi, Doriana, additional, Clerico, Marinella, additional, Signoriello, Elisabetta, additional, Frau, Jessica, additional, Ferrò, Maria Teresa, additional, Di Sapio, Alessia, additional, Pasquali, Livia, additional, Ulivelli, Monica, additional, Marinelli, Fabiana, additional, Callari, Graziella, additional, Iodice, Rosa, additional, Liberatore, Giuseppe, additional, Caleri, Francesca, additional, Repice, Anna Maria, additional, Cordera, Susanna, additional, Battaglia, Mario Alberto, additional, Salvetti, Marco, additional, Franciotta, Diego, additional, Uccelli, Antonio, additional, Maglione, Alessandro, additional, Signori, Alessio, additional, Iovino, Aniello, additional, Nicoletti, Carolina Gabri, additional, Mancinelli, Chiara Rosa, additional, Bezzini, Daiana, additional, Carmagnini, Daniele, additional, Brogi, Davide, additional, Orazio, Eduardo Nobile, additional, Cocco, Eleonora, additional, Nako, Enri, additional, Assandri, Ester, additional, Baldi, Federica, additional, Ansaldi, Filippo, additional, Bovis, Francesca, additional, Siciliano, Gabriele, additional, Cola, Gaia, additional, Lus, Giacomo, additional, Icardi, Giancarlo, additional, bellucci, gianmarco, additional, Rin, Giorgio Da, additional, Marfia, Girolama Alessandra, additional, Vazzoler, Giulia, additional, Trivelli, Giuseppe, additional, Maietta, Ilaria, additional, Sticchi, Laura, additional, Lorefice, Lorena, additional, Ruggiero, Lucia, additional, Manzino, Marcello, additional, Bragadin, Margherita Monti, additional, Buscarinu, Maria Chiara, additional, Gagliardi, Maria, additional, Sormani, Maria Pia, additional, Rilla, Maria Teresa, additional, Ponzano, Marta, additional, Fronza, Marzia, additional, Sette, Massimo Del, additional, Scialabba, Matteo, additional, Bedognetti, Michele, additional, De Rossi, Nicola, additional, De Stefano, Nicola, additional, Bigi, Rachele, additional, Dubbioso, Raffaele, additional, Reniè, Roberta, additional, Fabbri, Sabrina, additional, Rasia, Sarah, additional, Rolla, Simona, additional, Platzgummer, Stefan, additional, and Carlini, Valentina, additional
- Published
- 2021
- Full Text
- View/download PDF
22. A diagnostic score for anti-myelin-associated-glycoprotein neuropathy or chronic inflammatory demyelinating polyradiculoneuropathy in patients with anti-myelin-associated-glycoprotein antibody
- Author
-
Pietro E. Doneddu, Marta Ruiz, Elisa Bianchi, Giuseppe Liberatore, Fiore Manganelli, Dario Cocito, Giuseppe Cosentino, Luana Benedetti, Girola A. Marfia, Massimiliano Filosto, Chiara Briani, Claudia Giannotta, Eduardo Nobile‐Orazio, Doneddu, Pietro E, Ruiz, Marta, Bianchi, Elisa, Liberatore, Giuseppe, Manganelli, Fiore, Cocito, Dario, Cosentino, Giuseppe, Benedetti, Luana, Marfia, Girola A, Filosto, Massimiliano, Briani, Chiara, Giannotta, Claudia, and Nobile-Orazio, Eduardo
- Subjects
antibody ,chronic inflammatory demyelinating polyradiculoneuropathy ,CIDP ,diagnostic criteria ,MAG ,neuropathy ,Neurology ,Settore MED/26 - Neurologia ,Neurology (clinical) ,Settore MED/26 - Abstract
Background and purpose: A diagnostic score was developed to discriminate anti-myelin-associated-glycoprotein (MAG) neuropathy from chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and applied it to patients with atypical anti-MAG neuropathy. Methods: The clinical and electrophysiological features of patients with a diagnosis of typical anti-MAG neuropathy were compared to those of patients with a diagnosis of CIDP. The association of each feature with the diagnosis was assessed in the two groups. Features showing a significant association with the diagnosis were included in a multivariable logistic regression model and adjusted odds ratios were estimated for each feature. A score ranging from 1 to 3 was applied to each feature based on the magnitude of the estimated odds ratios. The score was then applied to patients with a clinical diagnosis of CIDP who also had high anti-MAG antibody titers (CIDP-MAG). Results: Thirty-one anti-MAG neuropathy patients, 45 typical CIDP patients and 16 CIDP-MAG patients were included. Scores in anti-MAG antibody patients ranged from 1 to 5 and in CIDP patients from -7 to -1. Using the score, 4/16 CIDP-MAG patients were diagnosed to have anti-MAG neuropathy and 12/16 patients to have CIDP. Response to intravenous immunoglobulin in the CIDP-MAG patients classified as CIDP was similar to that of definite CIDP patients and higher than that of anti-MAG neuropathy patients. Conclusions: Our score allowed an accurate discrimination to be made, amongst patients with anti-MAG antibodies, of those affected by CIDP and the patients with anti-MAG neuropathy. This score may help proper treatment to be chosen for patients with anti-MAG antibodies with a CIDP-like presentation.
- Published
- 2022
23. Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies
- Author
-
Schiavetti, I., Cordioli, C., Stromillo, M. L., Teresa Ferro, M., Laroni, A., Cocco, E., Cola, G., Pasquali, L., Rilla, M. T., Signoriello, E., Iodice, R., Di Sapio, A., Lanzillo, R., Caleri, F., Annovazzi, P., Conte, A., Liberatore, G., Ruscica, F., Docimo, R., Bonavita, S., Ulivelli, M., Cavalla, P., Patti, F., Ferraro, D., Clerico, M., Immovilli, P., Di Filippo, M., Salvetti, M., Sormani, M. P., the Breakthrough infections in MS study group, De Stefano, N., Bezzini, D., Giannotta, A., Schiavetti, Irene, Cordioli, Cinzia, Stromillo, Maria Laura, Teresa Ferrò, Maria, Laroni, Alice, Cocco, Eleonora, Cola, Gaia, Pasquali, Livia, Rilla, Maria Teresa, Signoriello, Elisabetta, Iodice, Rosa, Di Sapio, Alessia, Lanzillo, Roberta, Caleri, Francesca, Annovazzi, Pietro, Conte, Antonella, Liberatore, Giuseppe, Ruscica, Francesca, Docimo, Renato, Bonavita, Simona, Ulivelli, Monica, Cavalla, Paola, Patti, Francesco, Ferraro, Diana, Clerico, Marinella, Immovilli, Paolo, Di Filippo, Massimiliano, Salvetti, Marco, and Sormani, Maria Pia
- Subjects
COVID-19 Vaccines ,COVID-19 vaccination ,Fingolimod Hydrochloride ,SARS-CoV-2 ,COVID-19 Vaccine ,breakthrough infections ,breakthrough infection ,COVID-19 ,Multiple sclerosis ,Neurology ,Retrospective Studie ,Humans ,Multiple sclerosi ,Neurology (clinical) ,Human ,Retrospective Studies - Abstract
Background: Patients with multiple sclerosis (pwMS) treated with anti-CD20 or fingolimod showed a reduced humoral response to SARS-CoV-2 vaccines. Objective: In this study we aimed to monitor the risk of breakthrough SARS-CoV-2 infection in pwMS on different disease-modifying therapies (DMTs). Methods: Data on the number of vaccinated patients and the number of patients with a breakthrough infection were retrospectively collected in 27 Italian MS centers. We estimated the rate of breakthrough infections and of infection requiring hospitalization per DMT. Results: 19,641 vaccinated pwMS were included in the database. After a median follow-up of 8 months, we observed 137 breakthrough infections. Compared with other DMTs, the rate of breakthrough infections was significantly higher on ocrelizumab (0.57% vs 2.00%, risk ratio (RR) = 3.55, 95% CI = 2.74–4.58, p Conclusions: The risk of breakthrough SARS-CoV-2 infections is higher in patients treated with ocrelizumab and fingolimod, and the rate of severe infections was significantly reduced in all the DMTs excluding ocrelizumab.
- Published
- 2022
24. Comparison of the diagnostic accuracy of the 2021 EAN/PNS and 2010 EFNS/PNS diagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy
- Author
-
Pietro Emiliano Doneddu, Alberto De Lorenzo, Fiore Manganelli, Dario Cocito, Raffaella Fazio, Chiara Briani, Anna Mazzeo, Massimiliano Filosto, Giuseppe Cosentino, Luana Benedetti, Angelo Schenone, Girolama Alessandra Marfia, Giovanni Antonini, Sabrina Matà, Marco Luigetti, Giuseppe Liberatore, Emanuele Spina, Erdita Peci, Camilla Strano, Mario Cacciavillani, Luca Gentile, Stefano Cotti Piccinelli, Andrea Cortese, Elisa Bianchi, Eduardo Nobile-Orazio, Doneddu, Pietro Emiliano, De Lorenzo, Alberto, Manganelli, Fiore, Cocito, Dario, Fazio, Raffaella, Briani, Chiara, Mazzeo, Anna, Filosto, Massimiliano, Cosentino, Giuseppe, Benedetti, Luana, Schenone, Angelo, Marfia, Girolama Alessandra, Antonini, Giovanni, Matà, Sabrina, Luigetti, Marco, Liberatore, Giuseppe, Spina, Emanuele, Peci, Erdita, Strano, Camilla, Cacciavillani, Mario, Gentile, Luca, Cotti Piccinelli, Stefano, Cortese, Andrea, Bianchi, Elisa, and Nobile-Orazio, Eduardo
- Subjects
Neural Conduction ,neuroimmunology ,Settore MED/26 ,Sensitivity and Specificity ,Psychiatry and Mental health ,EMG ,Polyradiculoneuropathy, Chronic Inflammatory Demyelinating ,Neurology ,Humans ,Surgery ,neuropathy ,Neurology (clinical) ,Peripheral Nerves ,neuromuscular ,neurophysiology ,Retrospective Studies - Abstract
ObjectivesTo compare the sensitivity and specificity of the 2021 European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) diagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) with those of the 2010 European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS).MethodsSensitivity and specificity of the two sets of criteria were evaluated in 330 patients with CIDP and 166 axonal peripheral neuropathy controls. Comparison of the utility of nerve conduction studies with different number of nerves examined and of the sensitivity and specificity of the two criteria in typical CIDP and its variants were assessed.ResultsEFNS/PNS criteria had a sensitivity of 92% for possible CIDP and 85% for probable/definite CIDP, while the EAN/PNS criteria had a sensitivity of 83% for possible CIDP and 74% for CIDP. Using supportive criteria, the sensitivity of the EAN/PNS criteria for possible CIDP increased to 85% and that of CIDP to 77%, remaining lower than that of the EFNS/PNS criteria. Specificity of the EFNS/PNS criteria was 68% for possible CIDP and 84% for probable/definite CIDP, while the EAN/PNS criteria had a specificity of 88% for possible CIDP and 98% for CIDP. More extended studies increased the sensitivity of both sets of criteria by 4%–7% but reduced their specificity by 2%–3%. The EFNS/PNS criteria were more sensitive for the diagnosis of typical CIDP while the EAN/PNS criteria were more specific for the diagnosis of distal and sensory CIDP.ConclusionsIn our population, the EAN/PNS criteria were more specific but less sensitive than the EFNS/PNS criteria. With the EAN/PNS criteria, more extended nerve conduction studies are recommended to obtain an acceptable sensitivity while maintaining a high specificity.
- Published
- 2022
25. Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy
- Author
-
Maria Pia Sormani, Irene Schiavetti, Matilde Inglese, Luca Carmisciano, Alice Laroni, Caterina Lapucci, Valeria Visconti, Carlo Serrati, Ilaria Gandoglia, Tiziana Tassinari, Germana Perego, Giampaolo Brichetto, Paola Gazzola, Antonio Mannironi, Maria Laura Stromillo, Cinzia Cordioli, Doriana Landi, Marinella Clerico, Elisabetta Signoriello, Eleonora Cocco, Jessica Frau, Maria Teresa Ferrò, Alessia Di Sapio, Livia Pasquali, Monica Ulivelli, Fabiana Marinelli, Matteo Pizzorno, Graziella Callari, Rosa Iodice, Giuseppe Liberatore, Francesca Caleri, Anna Maria Repice, Susanna Cordera, Mario Alberto Battaglia, Marco Salvetti, Diego Franciotta, Antonio Uccelli, Alessandro Maglione, Alessio Signori, Aniello Iovino, Carolina Gabri Nicoletti, Chiara Rosa Mancinelli, Daiana Bezzini, Daniele Carmagnini, Davide Brogi, Eduardo Nobile Orazio, Enri Nako, Ester Assandrir, Federica Baldi, Filippo Ansaldi, Francesca Bovis, Gabriele Siciliano, Gaia Cola, Giacomo Lus, Giancarlo Icardi, Gianmarco Bellucci, Giorgio Da Rin, Girolama Alessandra Marfia, Giulia Vazzoler, Giuseppe Trivelli, Ilaria Maietta, Laura Sticchi, Lorena Lorefice, Lucia Ruggiero, Marcello Manzino, Margherita Monti Bragadin, Maria Chiara Buscarinu, Maria Gagliardi, Maria Teresa Rilla, Marta Ponzano, Marzia Fronza, Massimo Del Sette, Matteo Scialabba, Michele Bedognetti, Nicola De Rossi, Nicola De Stefano, Rachele Bigi, Raffaele Dubbioso, Roberta Reniè, Sabrina Fabbri, Sarah Rasia, Simona Rolla, Stefan Platzgummer, Valentina Carlini, Sormani, Maria Pia, Schiavetti, Irene, Inglese, Matilde, Carmisciano, Luca, Laroni, Alice, Lapucci, Caterina, Visconti, Valeria, Serrati, Carlo, Gandoglia, Ilaria, Tassinari, Tiziana, Perego, Germana, Brichetto, Giampaolo, Gazzola, Paola, Mannironi, Antonio, Stromillo, Maria Laura, Cordioli, Cinzia, Landi, Doriana, Clerico, Marinella, Signoriello, Elisabetta, Cocco, Eleonora, Frau, Jessica, Ferrò, Maria Teresa, Di Sapio, Alessia, Pasquali, Livia, Ulivelli, Monica, Marinelli, Fabiana, Pizzorno, Matteo, Callari, Graziella, Iodice, Rosa, Liberatore, Giuseppe, Caleri, Francesca, Repice, Anna Maria, Cordera, Susanna, Battaglia, Mario Alberto, Salvetti, Marco, Franciotta, Diego, and Uccelli, Antonio
- Subjects
Vaccines, Synthetic ,Vaccines ,COVID-19 Vaccines ,Multiple Sclerosis ,SARS-CoV-2 ,Messenger ,Vaccination ,Synthetic ,Breakthrough infections ,COVID-19 ,Disease Modifying Treatments ,Cohort Studies ,Humans ,Prospective Studies ,RNA, Messenger ,mRNA Vaccines ,Viral Vaccines ,General Medicine ,Settore MED/26 ,General Biochemistry, Genetics and Molecular Biology ,Breakthrough infection ,RNA ,Disease Modifying Treatment - Abstract
Background: In this study we aimed to monitor the risk of breakthrough SARS-CoV-2 infection in patients with MS (pwMS) under different DMTs and to identify correlates of reduced protection. Methods: This is a prospective Italian multicenter cohort study, long-term clinical follow-up of the CovaXiMS (Covid-19 vaccine in Multiple Sclerosis) study. 1855 pwMS scheduled for SARS-CoV-2 mRNA vaccination were enrolled and followed up to a mean time of 10 months. The cumulative incidence of breakthrough Covid-19 cases in pwMS was calculated before and after December 2021, to separate the Delta from the Omicron waves and to account for the advent of the third vaccine dose. Findings: 1705 pwMS received 2 m-RNA vaccine doses, 21/28 days apart. Of them, 1508 (88.5%) had blood assessment 4 weeks after the second vaccine dose and 1154/1266 (92%) received the third dose after a mean interval of 210 days (range 90-342 days) after the second dose. During follow-up, 131 breakthrough Covid-19 infections (33 during the Delta and 98 during the Omicron wave) were observed. The probability to be infected during the Delta wave was associated with SARS-CoV-2 antibody levels measured after 4 weeks from the second vaccine dose (HR=0.57, p 
- Published
- 2022
26. Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies.
- Author
-
Schiavetti I, Cordioli C, Stromillo ML, Teresa Ferrò M, Laroni A, Cocco E, Cola G, Pasquali L, Rilla MT, Signoriello E, Iodice R, Di Sapio A, Lanzillo R, Caleri F, Annovazzi P, Conte A, Liberatore G, Ruscica F, Docimo R, Bonavita S, Ulivelli M, Cavalla P, Patti F, Ferraro D, Clerico M, Immovilli P, Di Filippo M, Salvetti M, and Sormani MP
- Subjects
- COVID-19 Vaccines, Fingolimod Hydrochloride therapeutic use, Humans, Retrospective Studies, SARS-CoV-2, COVID-19, Multiple Sclerosis drug therapy, Multiple Sclerosis epidemiology
- Abstract
Background: Patients with multiple sclerosis (pwMS) treated with anti-CD20 or fingolimod showed a reduced humoral response to SARS-CoV-2 vaccines., Objective: In this study we aimed to monitor the risk of breakthrough SARS-CoV-2 infection in pwMS on different disease-modifying therapies (DMTs)., Methods: Data on the number of vaccinated patients and the number of patients with a breakthrough infection were retrospectively collected in 27 Italian MS centers. We estimated the rate of breakthrough infections and of infection requiring hospitalization per DMT., Results: 19,641 vaccinated pwMS were included in the database. After a median follow-up of 8 months, we observed 137 breakthrough infections. Compared with other DMTs, the rate of breakthrough infections was significantly higher on ocrelizumab (0.57% vs 2.00%, risk ratio (RR) = 3.55, 95% CI = 2.74-4.58, p < 0.001) and fingolimod (0.58% vs 1.62%, RR = 2.65, 95% CI = 1.75-4.00, p < 0.001), while there were no significant differences in any other DMT group. In the ocrelizumab group the hospitalization rate was 16.7% versus 19.4% in the pre-vaccination era (RR = 0.86, p = 0.74) and it was 3.9% in all the other DMT groups versus 11.9% in the pre-vaccination period (RR = 0.33, p = 0.02)., Conclusions: The risk of breakthrough SARS-CoV-2 infections is higher in patients treated with ocrelizumab and fingolimod, and the rate of severe infections was significantly reduced in all the DMTs excluding ocrelizumab.
- Published
- 2022
- Full Text
- View/download PDF
27. Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy.
- Author
-
Martín-Aguilar L, Lleixà C, Pascual-Goñi E, Caballero-Ávila M, Martínez-Martínez L, Díaz-Manera J, Rojas-García R, Cortés-Vicente E, Turon-Sans J, de Luna N, Suárez-Calvet X, Gallardo E, Rajabally Y, Scotton S, Jacobs BC, Baars A, Cortese A, Vegezzi E, Höftberger R, Zimprich F, Roesler C, Nobile-Orazio E, Liberatore G, Hiew FL, Martínez-Piñeiro A, Carvajal A, Piñar-Morales R, Usón-Martín M, Albertí O, López-Pérez MÁ, Márquez F, Pardo-Fernández J, Muñoz-Delgado L, Cabrera-Serrano M, Ortiz N, Bartolomé M, Duman Ö, Bril V, Segura-Chávez D, Pitarokoili K, Steen C, Illa I, and Querol L
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Retrospective Studies, Young Adult, Autoantibodies blood, Autoimmune Diseases of the Nervous System blood, Autoimmune Diseases of the Nervous System drug therapy, Autoimmune Diseases of the Nervous System immunology, Autoimmune Diseases of the Nervous System physiopathology, Cell Adhesion Molecules immunology, Immunologic Factors pharmacology, Nerve Growth Factors immunology, Ranvier's Nodes immunology, Rituximab pharmacology
- Abstract
Background and Objectives: To study the clinical and laboratory features of antineurofascin-155 (NF155)-positive autoimmune nodopathy (AN)., Methods: Patients with anti-NF155 antibodies detected on routine immunologic testing were included. Clinical characteristics, treatment response, and functional scales (modified Rankin Scale [mRS] and Inflammatory Rasch-built Overall Disability Scale [I-RODS]) were retrospectively collected at baseline and at the follow-up. Autoantibody and neurofilament light (NfL) chain levels were analyzed at baseline and at the follow-up., Results: Forty NF155+ patients with AN were included. Mean age at onset was 42.4 years. Patients presented with a progressive (75%), sensory motor (87.5%), and symmetric distal-predominant weakness in upper (97.2%) and lower extremities (94.5%), with tremor and ataxia (75%). Patients received a median of 3 (2-4) different treatments in 46 months of median follow-up. Response to IV immunoglobulin (86.8%) or steroids (72.2%) was poor in most patients, whereas 77.3% responded to rituximab. HLA-DRB1*15 was detected in 91.3% of patients. IgG4 anti-NF155 antibodies were predominant in all patients; anti-NF155 titers correlated with mRS within the same patient ( r = 0.41, p = 0.004). Serum NfL (sNfL) levels were higher in anti-NF155+ AN than in healthy controls (36.47 vs 7.56 pg/mL, p < 0.001) and correlated with anti-NF155 titers ( r = 0.43, p = 0.001), with I-RODS at baseline ( r = -0.88, p < 0.001) and with maximum I-RODS achieved ( r = -0.58, p = 0.01). Anti-NF155 titers and sNfL levels decreased in all rituximab-treated patients., Discussion: Anti-NF155 AN presents a distinct clinical profile and good response to rituximab. Autoantibody titers and sNfL are useful to monitor disease status in these patients. The use of untagged-NF155 plasmids minimizes the detection of false anti-NF155+ cases., Classification of Evidence: This study provides Class IV evidence that anti-NF155 antibodies associate with a specific phenotype and response to rituximab., (Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.